Globus Medical (GMED) Q3 FY2026 earnings: revenue $764 million, down 0.7% on the year

Globus Medical Inc. (GMED) reported revenue of $764 million for Q3 FY2026, the quarter ended 30 September 2026, down 0.7% on the same quarter a year earlier. Net income was $141 million, up 18.7% on the year, and diluted earnings per share $1.04. The figures are the company's own, from the 10-Q it filed with the SEC on 5 November 2026.

Revenue

$764 million

-0.7% on the year · -3.3% on the quarter

Q4 FY2024Q3 FY2026

Operating margin

23.2%

17.9% a year earlier

Q4 FY2024Q3 FY2026

Net income

$141 million

+18.7% on the year · -6.9% on the quarter

Q4 FY2024Q3 FY2026

Diluted EPS

$1.04

+18.2% on the year · -5.5% on the quarter

Q4 FY2024Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

What management said

Guidance figures: 1 lowered, 1 new, 1 kept.

Base business grew as Nevro sales fell: Worldwide net sales were $763.7 million, down 0.7%, or 0.5% in constant currency. Base business sales excluding Nevro rose 3.0% to $690.0 million; Nevro products fell to $73.7 million from $99.3 million.
Net income and GAAP EPS rose: GAAP net income was $141.2 million, up 18.7%. GAAP diluted EPS was $1.04 against $0.88 a year earlier, up 18.2%.
International sales declined: International net sales were $142.7 million, down 5.7% as reported and 5.0% in constant currency. International had grown 18.0% in the second quarter.

Read the earnings call summary

Income statement (profit and loss)

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Revenue	764	790	769	-3.3%	-0.7%
Cost of revenue	233	241	253	-3.5%	-7.8%
Gross profit	531	548	517	-3.2%	+2.8%
Gross margin	69.5%	69.4%	67.2%
Research and development	34.5	36.3	38.1	-4.9%	-9.3%
Selling, general and administrative	288	287	314	+0.6%	-8.0%
Operating income	178	182	137	-2.7%	+29.3%
Operating margin	23.2%	23.1%	17.9%
Pre-tax income	183	190	144	-3.5%	+27.3%
Income tax	42.1	38.2	25.0	+10.1%	+68.2%
Effective tax rate	23.0%	20.1%	17.4%
Net income	141	152	119	-6.9%	+18.7%
Net margin	18.5%	19.2%	15.5%
Diluted EPS	$1.04	$1.10	$0.88	-5.5%	+18.2%

$ million except per share.

Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Operating cash flow	265	210	250	+26.5%	+6.2%
Capital expenditure	40.4	33.2	35.8	+21.8%	+12.8%
Free cash flow	225	177	214	+27.3%	+5.1%
Free cash flow margin	29.4%	22.4%	27.8%
Cash from investing	-156	-129	-75.8
Cash from financing	-131	-134	-32.0
Depreciation and amortisation	70.9	70.1	71.1	+1.2%	-0.3%
Share-based compensation	11.7	13.4	11.5	-12.3%	+1.8%
Buybacks	143	136	40.0	+5.1%	+257.4%
Diluted shares, weighted	136m	137m	135m	-1.0%	+0.5%
Shares outstanding at period end	n/a	134m	134m

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Shareholders' equity	4,796	4,769	4,399	+0.6%	+9.0%
Debt	0.0	0.0	0.0
Operating lease liabilities	93.4	96.8	105	-3.5%	-11.1%
Finance lease liabilities	0.3	0.4	0.4	-14.2%	-23.7%
Other liabilities	638	622	591	+2.5%	+7.9%
Total liabilities and equity	5,528	5,488	5,096	+0.7%	+8.5%
Fixed assets	533	534	578	-0.1%	-7.8%
Goodwill	1,454	1,438	1,434	+1.1%	+1.3%
Intangible assets	667	693	774	-3.6%	-13.8%
Investments	430	333	35.4	+29.2%	+1,113.1%
Cash and equivalents	441	508	372	-13.1%	+18.7%
Receivables	675	692	619	-2.4%	+9.1%
Inventory	824	811	772	+1.6%	+6.8%
Other assets	504	480	512	+4.9%	-1.6%
Total assets	5,528	5,488	5,096	+0.7%	+8.5%

Questions

What was Globus Medical's revenue in Q3 FY2026?

Globus Medical (GMED) reported revenue of $764 million for Q3 FY2026, the quarter ended 30 September 2026, down 0.7% on the same quarter a year earlier.

How much did Globus Medical earn in Q3 FY2026?

Net income for Q3 FY2026 was $141 million, up 18.7% on the year, and diluted earnings per share $1.04.

When did Globus Medical report Q3 FY2026 results?

Globus Medical filed its 10-Q for the quarter ended 30 September 2026 with the SEC on 5 November 2026.

Quarterly results, the last 20 quarters

	Q4 FY2021 *	Q1 FY2022	Q2 FY2022	Q3 FY2022	Q4 FY2022 *	Q1 FY2023	Q2 FY2023	Q3 FY2023	Q4 FY2023 *	Q1 FY2024	Q2 FY2024 †	Q3 FY2024 †	Q4 FY2024 *	Q1 FY2025 †	Q2 FY2025	Q3 FY2025	Q4 FY2025 * †	Q1 FY2026	Q2 FY2026	Q3 FY2026
Revenue	250	231	264	254	274	277	292	384	617	607	630	626	657	598	745	769	826	760	790	764
Cost of revenue	61.8	59.2	68.5	65.5	70.6	70.8	76.5	135	265	241	260	271	263	195	249	253	261	234	241	233
Gross profit	188	171	195	189	204	206	215	248	351	365	370	355	394	403	497	517	565	526	548	531
Gross margin	75%	74%	74%	74%	74%	74%	74%	65%	57%	60%	59%	57%	60%	67%	67%	67%	68%	69%	69%	70%
R&D	51.0	17.4	17.4	18.7	19.5	21.1	21.3	29.3	52.3	57.3	37.7	35.4	33.4	33.1	40.0	38.1	36.2	36.5	36.3	34.5
SG&A	107	101	107	107	118	122	120	156	245	249	239	240	253	243	304	314	318	298	287	288
Operating income	18.2	46.4	67.8	59.7	54.0	56.4	66.2	0.4	10.1	8.0	49.6	48.1	60.3	97.0	76.1	137	169	150	182	178
Operating margin	7%	20%	26%	23%	20%	20%	23%	0%	2%	1%	8%	8%	9%	16%	10%	18%	20%	20%	23%	23%
Pre-tax income	19.8	48.9	70.5	61.5	62.1	63.2	74.7	2.5	25.0	-8.6	47.6	57.0	24.7	104	188	144	169	157	190	183
Tax rate	24%	22%	23%	23%	19%	22%	23%	61%	40%	n/a	33%	9%	-7%	27%	-8%	17%	17%	21%	20%	23%
Net income	15.1	38.1	54.6	47.4	50.1	49.1	57.7	1.0	15.0	-7.1	31.8	51.8	26.5	75.5	203	119	141	124	152	141
Net margin	6%	17%	21%	19%	18%	18%	20%	0%	2%	-1%	5%	8%	4%	13%	27%	15%	17%	16%	19%	18%
Diluted EPS	$0.15	$0.37	$0.53	$0.47	$0.49	$0.48	$0.57	$0.01	$0.11	-$0.05	$0.23	$0.38	$0.19	$0.54	$1.49	$0.88	$1.03	$0.90	$1.10	$1.04
Operating cash flow	76.3	44.7	36.9	32.9	64.0	53.3	35.0	50.5	105	52.4	54.3	204	210	177	77.9	250	249	202	210	265
Capital expenditure	17.0	20.0	23.8	12.0	18.3	16.0	17.9	21.5	22.9	28.6	27.8	42.0	17.1	36.1	46.6	35.8	46.2	39.6	33.2	40.4
Free cash flow	59.2	24.7	13.1	20.9	45.6	37.3	17.2	28.9	81.8	23.8	26.5	162	193	141	31.3	214	202	163	177	225
Buybacks	n/a	n/a	n/a	0.0	n/a	n/a	n/a	n/a	n/a	83.3	1.5	0.0	1.0	190	25.0	40.0	45.0	0.0	136	143
Shares outstanding	102m	102m	100m	100m	100m	100m	100m	138m	135m	135m	135m	136m	138m	135m	135m	134m	135m	136m	134m	n/a
Filing	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q

Each quarter as filed, linked to its filing.

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-Q for the period ended 30 September 2026, filed 5 November 2026: the filing.